Swiss drugmaker Novartis AG is considering working with reinsurers to provide alternative financing options for life-saving drugs, potentially saving substantial healthcare costs, Financial Times reported on Sunday.
Among the options proposed includes a “reinsurance model in which a third party underwrites the catastrophic case of a child having one of these conditions,” Novartis Chief Executive Officer Vas Narasimhan told the FT in an interview.
The FT has already said that reinsurance companies, which provide a return to their employer’s health insurance plans, could benefit from this new income while increasing competition from competing risk sources. Reinsurance companies can bring treatment costs together by different pharmaceutical companies in countries.
Discussions on the financing of new generation therapies, which may require a single infusion, but are costly, are in the conceptual stage, and the m reinsurance option t may also work for government-funded health systems such as the UK. insurance – based systems.
Legal warning !
The information, comments and suggestions there are not covered by investment advice. It is based on the author's personal opinions. These views may not fit your financial situation and risk and return preferences. For this reason, based solely on this information, investment decisions may not have the appropriate consequences for your expectation. Our Site is not responsible for any direct or indirect damages incurred by the investors as a result of the use of the information on the Site, deficiencies in the sources, damages incurred by profit, moral damages, or damage to third parties.